Pfizer agrees to allow generic versions of its COVID pill - Aljazeera.com | Canada News Media
Connect with us

Business

Pfizer agrees to allow generic versions of its COVID pill – Aljazeera.com

Published

 on


Pharmaceutical giant Pfizer has signed a deal enabling the production and supply of its experimental COVID anti-viral drug in dozens of lower- and middle-income countries.

The agreement between the US company and the UN-backed international public health group Medical Patent Pool (MPP) would allow producers to manufacture and supply generic versions of the drug in 95 countries without the threat of patent infringement.

Most of the countries included in the deal are in Africa and Asia, covering about 53 percent of the world’s population.

“Pfizer remains committed to bringing forth scientific breakthroughs to help end this pandemic for all people,” Albert Bourla, Pfizer’s chief executive, said on Tuesday.

“We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections, decreasing the strain on our healthcare systems and saving lives,” he added.

Later on Tuesday, Pfizer asked regulators in the United States to grant its pill emergency use authorisation. Generic companies can start preparations for the product once they get a licence, but have to wait for the regulatory approval before they can supply.

The company has said its late-stage trials showed the pill cut the chance of hospitalisation or death for adults at risk of severe disease by 89 percent. The trials evaluated data from 1,219 positive cases across North and South America, Europe, Africa, and Asia.

The drug has proven to be most effective if taken at an early stage of infection and in combination with an older antiviral called ritonavir.

Bourla told the Reuters news agency in early November that the company was considering several pricing options for low-income countries, with the goal of “no barrier for them as well to have access”.

Ellen ‘t Hoen, director of Medicines Law & Policy noted that the deal allows countries that are excluded from the list to ask generic companies to supply the product under a compulsory licence. “This is an important feature of the MPP’s license,” she said. Compulsory licensing is when governments allow to waive patents’ rights without the licence owner’s consent.

“With a small molecule like this – easy to make and probably already being developed by generics – a simple compulsory or voluntary licence is sufficient,” she said, noting that for vaccine production the process is more complex as companies need technology transfer on top of a licence.

“This is an important precedent, as Pfizer has not licensed any COVID-related technology so far. The hope now is that Pfizer will do its second step with the MPP by transferring technology to enable the production of its vaccine,” she added.

Regina Osih, a medical doctor and infectious diseases specialist at the Aurum Institute in Johannesburg, South Africa, said the deal was “very important”.

“These kind of deals enable everybody to potentially access COVID medicament – they are still going to exclude someone, but they will improve the conversation around equitable access,” she said.

Still, medical charity Doctors Without Borders (Medecins Sans Frontieres, or MSF) said it was “disheartened” by the agreement, noting that a number of countries including Argentina, Brazil, China, and Thailand were excluded from the agreement.

“We are disheartened to see yet another restrictive voluntary licence during this pandemic while cases continue to rise in many countries around the world,” said Yuanqiong Hu, a senior legal policy adviser with MSF Access Campaign.

“If Pfizer really wants to live up to its promise to contribute to equitable access to this new treatment, it should clearly state that they will not stand in the way of open generic production and competition, instead of signing restrictive voluntary licences, and lift any kind of intellectual property monopoly during this pandemic,” she said.

Pfizer’s move came after US pharmaceutical company Merck signed a similar royalty-free deal with the MPP last month to allow its anti-viral drug, molnupiravir, to be made and sold at low cost in 105 developing countries. Merck’s drug was approved by regulators in the UK earlier this month.

The moves by Pfizer and Merck to share the patents for their COVID-19 drugs came amid international pressure on pharmaceutical companies to share and transfer technologies to allow the production of generic versions of their COVID-19 vaccines. So far, Pfizer has refused to do so.

Critics have long argued that the reluctance to share vaccine recipes has contributed to the starkly uneven distribution of shots between rich and poor countries.

Only 4.6 percent of people in low-income countries have received at least one shot, according to Our World in Data. Globally, 7.54 billion doses have been administered.

“Imagine what would have happened if they (vaccines makers) would have licensed their technology in May 2020,” Hoen, referring to the date the World Health Organization launched the Technology Access Pool (C-TAP) platform for companies to share vaccines’ intellectual property and know-how.

“Then, we would have enabled production capacity even in areas where today it does not exist,” she said.

Adblock test (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version